Harry J. Gould, III

Dr. Gould is co-inventor with Dr. Paul of Targeted Osmotic Lysis (TOL). He is Professor of Neurology and Neuroscience at LSU Health Sciences Center (LSUHSC) and has been board certified in Neurology and Pain Management. Prior to obtaining his medical degree, he was Associate Professor of Anatomy at LSUHSC and Assistant Professor of Anatomy at the University of Cincinnati.

His long research collaboration with Dr. Paul on sodium channels and pumps in neuropathic pain situations led to their discovery of the mechanisms used in the TOL treatment for advanced cancer.

Dr. Gould's early research contributed to understanding the organization of sensory/motor systems in the cerebral cortex. He received his undergraduate training at the State University of New York at Stony Brook, his Ph.D. from Brown University, and his M.D. from LSU Health Sciences Center. He has served on scientific advisory boards for Elan Pharmaceuticals, Parke-Davis, Pfizer, Ortho-McNeil Pharmaceuticals, Novartis Pharmaceuticals, Alpharma, Inc. (currently King Pharmaceuticals), Endo Pharmaceuticals, Gilead Sciences, Inc. and Depomed, Inc.